Results 201 to 210 of about 112,698 (266)

MAFF Suppresses Necroptosis in Pancreatic Cancer via the GATA4‐MLKL Axis

Cancer Science, EarlyView.
MAFF promotes pancreatic cancer progression by acting as a transcriptional repressor of the GATA4‐MLKL axis, thereby inhibiting necroptotic cell death. This study identifies the MAFF‐GATA4‐MLKL pathway as a novel therapeutic target and a significant prognostic biomarker for pancreatic adenocarcinoma.
Xinwei Zhou, Zheng Zhao, Ning Sun, Daoyong Zhang   +3 more
wiley   +1 more source

Targeting Mitochondrial Vulnerabilities in Chronic Myeloid Leukemia: From Pathobiology to Novel Therapeutic Opportunities. [PDF]

Cancers (Basel)
Caprino F, Valentino I, Bruzzese A, Ganino L, Mesuraca M, Citraro R, Gentile M, Gallo Cantafio ME, Amodio N.   +8 more
europepmc   +1 more source

Integrated Transcriptomic and Functional Analyses Reveal lncRNA‐miRNA‐mRNA Axis in AML Relapse After Allo‐HSCT

Cancer Science, EarlyView.
Transcriptomic profiling of CD34+ cells from AML patients relapsing after allo‐HSCT reveals lncRNA‐driven ceRNA networks, with the SNHG8‐miR‐625‐ZC3H13/15 axis identified as a key relapse‐promoting module through CRISPR screening and single‐cell perturbation.
Fei Zhao, Wenhao Wang, Hongye Gao, Ping Zhu, Weihua Zhai, Yi He, Aiming Pang, Sizhou Feng, Mingzhe Han, Lina Wu, Shukai Qiao, Lei Zhang, Erlie Jiang, Xiaolei Pei, Donglin Yang   +14 more
wiley   +1 more source

Behcet's disease in a patient with chronic myeloid leukemia. [PDF]

Indian J Sex Transm Dis AIDS
Singh D, Somasundaram A, Gajula AS, Kumar S.   +3 more
europepmc   +1 more source

The Natural Quassinoid Brusatol Enhances Venetoclax Efficacy and Overcomes Resistance in Myeloid Leukemias

Cancer Science, EarlyView.
Schematic illustration of the mechanisms by which the natural quassinoid brusatol induces apoptosis in myeloid leukemias and enhances venetoclax efficacy via p53‐dependent apoptosis and mitochondrial dysfunction. ABSTRACT While venetoclax‐based combinations have shown promising results in acute myeloid leukemia (AML), the remission duration is ...
Shin‐ichiro Kawaguchi, Kazuya Sato, Junko Izawa, Norihito Takayama, Hiroko Hayakawa, Ken Suzaki, Susumu Goyama, Chiyoko Kato, Eiji Sakashita, Kaoru Tominaga, Hitoshi Endo, Yoshinobu Kanda   +11 more
wiley   +1 more source

ITGA5 as a Dual Regulator of Epithelial‐Mesenchymal Transition and Epithelial Cell Anoikis Resistance: Functional Validation and Drug Prediction

Cell Proliferation, EarlyView.
Proteomics and functional validation reveal ITGA5 as a dual promoter of epithelial‐mesenchymal transition and anoikis resistance in human bronchial epithelium: targeting ITGA5 represents a novel therapeutic strategy for asthma airway remodelling. ABSTRACT Airway remodelling is a major contributor to persistent airflow limitation and irreversible lung ...
Ting Wang, Ling Rao, Xiaofang Li, Miaofen Zhang, Huiting Huang, Zhiyan Luo, Gang Liao, Yong Jiang, Shaofeng Zhan, Qiong Liu, Xiufang Huang   +10 more
wiley   +1 more source

Chronic Myeloid Leukemia and the T315I <i>BCR::ABL1</i> Mutation. [PDF]

Int J Mol Sci
Pierro F, Stella S, Fazio M, Russo S, Massimino M, Mirabile G, Belletti D, Allegra A, Stagno F.   +8 more
europepmc   +1 more source

A Rare Case of Cutaneous Extramedullary Hematopoiesis in Chronic Myeloid Leukemia

Journal of Cutaneous Pathology, EarlyView.
ABSTRACT Cutaneous extramedullary hematopoiesis (CEH) is a rare manifestation of extramedullary hematopoiesis (EMH), a process typically associated with fetal development or myeloproliferative neoplasms. EMH most commonly involves the spleen, liver, and lymph nodes, with CEH being exceedingly rare in chronic myeloid leukemia (CML).
Bennett Christie‐Nguyen, Hanadi El Achi, Levani Iashvili, Amer Wahed, Brenda Mai, Jacob Armstrong   +5 more
wiley   +1 more source

Evaluating comorbidity scoring systems for flumatinib therapy in chronic myeloid leukemia: a machine learning and SHAP-based predictive analysis. [PDF]

Front Med (Lausanne)
Yang Y, Li Y, Wang J.
europepmc   +1 more source

Patients' and healthcare providers' views regarding dose reduction of tyrosine kinase inhibitors in chronic myeloid leukemia: a qualitative study. [PDF]

Oncologist
Lokhorst DN, van den Bemt BJF, Smit Y, Hermens RPMG, Blijlevens NMA, Bekker CL.   +5 more
europepmc   +1 more source